Literature DB >> 17314166

Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2.

Philippe Veron1, Valérie Allo, Christel Rivière, Jacky Bernard, Anne-Marie Douar, Carole Masurier.   

Abstract

Dendritic cells (DC) are antigen-presenting cells pivotal for inducing immunity or tolerance. Gene transfer into DC is an important strategy for developing immunotherapeutic approaches against infectious pathogens and cancers. One of the vectors previously described for the transduction of human monocytes or DC is the recombinant adeno-associated virus (rAAV), with a genome conventionally packaged as a single-stranded (ss) molecule. Nevertheless, its use is limited by the poor and variable transduction efficiency of DC. In this study, AAV type 1 (AAV1) and AAV2 vectors, which expressed the enhanced green fluorescent protein and were packaged as ss or self-complementary (sc) duplex strands, were used to transduce different DC subsets generated ex vivo and the immunophenotypes, states of differentiation, and functions of the subsets were carefully examined. We show here for the first time that a single exposure of monocytes (M(o)) or CD34(+) progenitors (CD34) to sc rAAV1 or sc rAAV2 leads to high transduction levels (5 to 59%) of differentiated M(o)-DC, M(o)-Langerhans cells (LC), CD34-LC, or CD34-plasmacytoid DC (pDC), with no impact on their phenotypes and functional maturation of these cells, compared to those of exposure to ss rAAV. Moreover, we show that all these DC subpopulations can also be efficiently transduced after commitment to their differentiation pathways. Furthermore, these DC subsets transduced with sc rAAV1 expressing a tumor antigen were potent activators of a CD8(+)-T-cell clone. Altogether, these results show the high potential of sc AAV1 and sc AAV2 vectors to transduce ex vivo conventional DC, LC, or pDC or to directly target them in vivo for the design of new DC-based immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314166      PMCID: PMC1900227          DOI: 10.1128/JVI.02516-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  Tolerogenic dendritic cells.

Authors:  Ralph M Steinman; Daniel Hawiger; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints.

Authors:  Redouane Rouas; Rathviro Uch; Yvette Cleuter; François Jordier; Claude Bagnis; Patrice Mannoni; Philippe Lewalle; Philippe Martiat; Anne Van den Broeke
Journal:  Cancer Gene Ther       Date:  2002-09       Impact factor: 5.987

4.  Double strand interaction is the predominant pathway for intermolecular recombination of adeno-associated viral genomes.

Authors:  Yongping Yue; Dongsheng Duan
Journal:  Virology       Date:  2003-08-15       Impact factor: 3.616

Review 5.  Immature, but not inactive: the tolerogenic function of immature dendritic cells.

Authors:  Karsten Mahnke; Edgar Schmitt; Laura Bonifaz; Alexander H Enk; Helmut Jonuleit
Journal:  Immunol Cell Biol       Date:  2002-10       Impact factor: 5.126

Review 6.  From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.

Authors:  Melissa Dullaers; Kris Thielemans
Journal:  J Gene Med       Date:  2006-01       Impact factor: 4.565

7.  Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector.

Authors:  Y Liu; M Chiriva-Internati; F Grizzi; E Salati; J J Roman; S Lim; P L Hermonat
Journal:  Cancer Gene Ther       Date:  2001-12       Impact factor: 5.987

8.  Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.

Authors:  Z Wang; H-I Ma; J Li; L Sun; J Zhang; X Xiao
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

9.  Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo.

Authors:  D M McCarty; H Fu; P E Monahan; C E Toulson; P Naik; R J Samulski
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

10.  BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction.

Authors:  A Dzionek; Y Sohma; J Nagafune; M Cella; M Colonna; F Facchetti; G Günther; I Johnston; A Lanzavecchia; T Nagasaka; T Okada; W Vermi; G Winkels; T Yamamoto; M Zysk; Y Yamaguchi; J Schmitz
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  20 in total

1.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 2.  Directing dendritic cell immunotherapy towards successful cancer treatment.

Authors:  Rachel Lubong Sabado; Nina Bhardwaj
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

3.  Regulatory and Exhausted T Cell Responses to AAV Capsid.

Authors:  Gwladys Gernoux; James M Wilson; Christian Mueller
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

4.  Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8+ T Cell Responses Independently of Transgene Expression in DCs.

Authors:  Alexandre Ghenassia; David-Alexandre Gross; Stéphanie Lorain; Fabiola Tros; Dominique Urbain; Sofia Benkhelifa-Ziyyat; Alain Charbit; Jean Davoust; Pascal Chappert
Journal:  Mol Ther       Date:  2017-07-15       Impact factor: 11.454

5.  High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.

Authors:  George V Aslanidi; Angela E Rivers; Luis Ortiz; Lakshmanan Govindasamy; Chen Ling; Giridhara R Jayandharan; Sergei Zolotukhin; Mavis Agbandje-McKenna; Arun Srivastava
Journal:  Vaccine       Date:  2012-04-10       Impact factor: 3.641

6.  Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs.

Authors:  Virginia Haurigot; Federico Mingozzi; George Buchlis; Daniel J Hui; Yifeng Chen; Etiena Basner-Tschakarjan; Valder R Arruda; Antoneta Radu; Helen G Franck; J Fraser Wright; Shangzhen Zhou; Hansell H Stedman; Dwight A Bellinger; Timothy C Nichols; Katherine A High
Journal:  Mol Ther       Date:  2010-04-27       Impact factor: 11.454

7.  HIV-1 gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1.

Authors:  Appakkudal R Anand; Anil Prasad; Ritu R Bradley; Yadwinder S Deol; Tirumuru Nagaraja; Xianghui Ren; Ernest F Terwilliger; Ramesh K Ganju
Journal:  Blood       Date:  2009-08-21       Impact factor: 22.113

8.  Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.

Authors:  Munjal Pandya; Kellee Britt; Brad Hoffman; Chen Ling; George V Aslanidi
Journal:  J Immunother       Date:  2015-09       Impact factor: 4.456

9.  Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors.

Authors:  Yuanqing Lu; Sihong Song
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-22       Impact factor: 11.205

10.  Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation.

Authors:  Philippe Veron; Sylvie Boutin; Samia Martin; Laurence Chaperot; Joel Plumas; Jean Davoust; Carole Masurier
Journal:  J Transl Med       Date:  2009-01-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.